Efficacy and safety of molecularly targeted agents and immune checkpoint inhibitors for unresectable or recurrent/metastatic oral cancer in Japan
Background/purpose: For unresectable recurrent/metastatic head and neck cancer, pembrolizumab alone or pembrolizumab combined with cisplatin and 5-fluorouracil is the first-line therapy, depending on the PD-L1 combined positive score (CPS). However, this is based on clinical studies of head and neck...
| Автори: | , , , , , , , , , , , , , |
|---|---|
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Elsevier
2024-07-01
|
| Серія: | Journal of Dental Sciences |
| Предмети: | |
| Онлайн доступ: | http://www.sciencedirect.com/science/article/pii/S1991790223003914 |